歐康維視生物-B(01477.HK)公布，OT-702(阿柏西普眼內注射溶液，EYLEA生物類似藥)的III期臨床試驗已成功在中國完成。
OT-702由集團及其合作夥伴博安生物(06955.HK)合作研發。OT-702的III期臨床研究由雙方合作開展，其新藥申請將於近期向國家藥監局藥品審評中心遞交。
歐康維視生物-B(01477.HK)阿柏西普眼內注射溶液於內地完成III期臨床試驗
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.